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Abstract
Purpose Recurrence after pituitary surgery in Cushing’s disease (CD) is a common problem ranging from 5% (minimum) to
50% (maximum) after initially successful surgery, respectively. In this review, we give an overview of the current literature
regarding prevalence, diagnosis, and therapeutic options of recurrent CD.
Methods We systematically screened the literature regarding recurrent and persistent Cushing’s disease using the MESH
term Cushing’s disease and recurrence. Of 717 results in PubMed, all manuscripts in English and German published
between 1980 and April 2020 were screened. Case reports, comments, publications focusing on pediatric CD or CD in
veterinary disciplines or studies with very small sample size (patient number < 10) were excluded. Also, papers on CD in
pregnancy were not included in this review.
Results and conclusions Because of the high incidence of recurrence in CD, annual clinical and biochemical follow-up is
paramount. 50% of recurrences occur during the first 50 months after first surgery. In case of recurrence, treatment options
include second surgery, pituitary radiation, targeted medical therapy to control hypercortisolism, and bilateral adrena-
lectomy. Success rates of all these treatment options vary between 25 (some of the medical therapy) and 100% (bilateral
adrenalectomy). All treatment options have specific advantages, limitations, and side effects. Therefore, treatment decisions
have to be individualized according to the specific needs of the patient.
Keywords Hypercortisolism ● Cushing’s syndrome ● Pituitary adenoma ● Adrenostatic therapy
Introduction
Cushing’s syndrome (CS) is in 60–85% of cases ACTH-
dependent. Most frequently it is caused by a corticotroph
adenoma of the pituitary gland [1]. The recommended
screening tests for hypercortisolism include the low-dose
dexamethasone suppression test (LDDST with 1 mg),
urinary free cortisol in a 24 h-output-collection (UFC), and
midnight salivary cortisol measurement. The tests for sub-
typing include the high-dose-dexamethasone suppression
test, the CRH test, and in some cases the inferior petrosal
sampling. According to recent systematic meta-analyses,
first-line therapy is transsphenoidal surgery which leads to
remission in 71% [2], 80% [3] or 78% of cases [4]. How-
ever, there are still open questions regarding diagnosis and
therapy of recurrent CD. To summarize the current research
in this field and to identify knowledge gaps, we conducted a
systematic review.
Methods
We systematically screened the literature regarding recur-
rent and persistent Cushing’s disease (CD) using the MESH
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term Cushing’s disease and recurrence in PubMed. We
identified 717 studies published between 1980 and April
2020, of which 692 were in English or German. Of these
manuscripts, 134 were fully considered after excluding case
reports, comments, reviews without meta-analysis, pub-
lications focusing on pediatric CD or CD in veterinary
disciplines, CD in pregnancy and very small studies with
sample size <10 patients. Table 1 summarizes major studies
with ≥100 patients with CD published between 1983 and
2018 in which recurrence after first transsphenoidal surgery
was analyzed.
Definition of recurrence and persistency
Remission following transsphenoidal surgery is most often
defined by low morning cortisol levels (<1.8 µg/dl; 50 nmol/
L) [5] and the requirement of glucocorticoid replacement
therapy. Obviously, there may be patients who do not fulfill
this cut-off but still enter remission. In contrast to disease
persistence after transsphenoidal surgery, the definition of
recurrence requires a phase of months to years of disease
remission, which then is followed by re-appearance of CD.
Remission criteria vary between studies (see Table 1),
which is one possible explanation for different remission
and recurrence rates in different studies. While remission
criteria are not standardized, recurrence criteria are also not
consistent throughout different studies. Most of the studies
define recurrence by an elevated UFC or elevated serum
cortisol—criteria, which are not the most sensitive and
specific markers.
Diagnosis of recurrence
Prevalence of recurrence after pituitary surgery
CD recurs in ~14% of patients (5–21%) between 3 and
158 months (mean 51 months) [4]. Fifty percent of relapses
occur during the first 15–50 months after initial surgery [6].
However, late recurrences after decades of remission are
possible [7]. A regular follow-up is therefore mandatory and
a consistent recommendation in several studies and guide-
lines [8–11]. Recurrence rates differ greatly between the
studies, most likely due to varying definitions of remission
and recurrence, and also due to different surgical approaches
and length of follow-up [12]. The recurrence rate is higher
with longer follow-up, as already stated in 1992 by Tahir
and Sheeler and shown in Table 1 [13]. In addition, com-
parisons among studies is difficult since, for example, few
patients with negative MRI at baseline are included in some
series [14], a factor that influences success greatly [15].
According to our research, recurrence of CD is mostly
defined by biochemical criteria, while clinical signs and
symptoms are often not mentioned and, therefore, apparently
not compulsory. This scenario creates a level of ambiguity
since biochemical evidence of hypercortisolism is not per se
specific and sensitive. Examples for the latter are mild
recurrence or cyclic CS [16] and for the former physiological
forms of hypercortisolism (i.e., in major depression), which
can also be typical in the postoperative phase of CD.
According to a recent multicenter study by Geer et al. the
clinical practice situation in the US shows that transsphe-
noidal surgery is in more than 50% of the cases initially
unsuccessful [17]. This study was retrospective based on
data from medical records from 230 patients. Mean follow-
up was quite short with 3 years (median 1.9, range 0–27.5
years) and a lot of data were missing. For example, there
were no MRI results available for 90 patients [17]. After
initial surgery, only 91 patients were in remission and, at the
end of the observation period, 110 patients (49.1%)
achieved remission using additional treatment strategies.
Remission was not achieved in the other 67 patients, data of
47 patients were missing. Summarized, results from this
study should be evaluated with caution as outcome differs
greatly from results of recent meta-analysis. However, it is a
warning signal that surgical series from expert neurosurgery
centers may not reflect real world scenarios, in which access
to expert centers and optimized follow-up may be limited.
Factors influencing recurrence
Many studies have focused on factors influencing the
remission state of patients with CD (summary shown in
Table 2). In a single-center study, remission rates in mac-
roadenomas are higher than in microadenomas [18], oppo-
site to the findings of a recent metanalysis [19] and most of
the other studies. Experience of the surgeon influences
outcome, morbidity, and mortality [4, 20]. In a multicenter,
retrospective European study of 668 patients remission rates
were associated with pre-surgical identification of the tumor
by MRI, an observation also reported by Chee et al. [21]. It
was also higher in patients with long-term glucocorticoid
replacement therapy and those with low postoperative cor-
tisol levels [7], whereas only a minority did not confirm the
latter [22–24].
According to a study by Liu et al. using different
machine learning algorithms, the most important predictors
for recurrence were young age, postoperative serum corti-
sol, and postoperative ACTH, both measured in the first
7 days after surgery (cut-offs see Table 2) [25]. However,
sensitivity and specificity using such an algorithm were
quite low with 87% and 58%, respectively.
In a retrospective study with 41 patients with CD, higher
ACTH levels pre-surgery were one predictor for recurrence,
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of BMI after treatment were factors that were associated
with remission [26]. Furthermore, recurrence is also influ-
enced by the presence of somatic USP8 mutations and is
significantly more frequent in patients with USP8 mutant
corticotroph tumors [27]. Duration of symptoms until first
surgery does not influence remission rate [28]. Another
matter of debate are patients in whom a corticotroph pitui-
tary adenoma is not identified histologically. In a study by
Pouratian, an adenoma could not be confirmed by pathology
in 111 out of 490 cases. Of these patients, only 50%
achieved remission compared with 88% of patients with
histologically confirmed adenoma [29]. Furthermore, these
patients had higher rates of early recurrence within the first
months after surgery [29]. In another study focusing on the
pathology, recurrence was associated with the lack of peri-
tumoral Crooke’s change [30] but this finding was not
confirmed in a larger study [31]. However, it should be kept
in mind that rate of diagnostic errors (misdiagnoses) in
pathology ranges between 3–9% [32] and, therefore, false-
negative and false-positive results are not uncommon. In a
meta-analysis by Roelfsema, only postoperative hormone
levels remained a prognostic factor for remission—as shown
in 20 studies—while other factors such as age, gender,
tumor size, and invasion were unrelated to recurrence [2].
Diagnosis of recurrence
Surveillance of patients in remission: how often
performing follow-up studies?
It is a widely accepted practice to recommend screening of
patients with a history of CD on a regular basis. The rational,
as outlined above, is the lack of a reliable prediction model
as no single or combined clinical or biochemical parameter
can exclude future recurrence with acceptable precision
[33, 34]. Currently, there is no consensus recommendation
on the intervals of clinical and/or biochemical follow-up.
Ayala et al. recommend to screen patients in different
intervals—3 months to annually—depending on morning
serum cortisol levels measured 2–3 days post-surgery [9].
Fleseriu et al. recommend to evaluate patients clinically on
an annual basis [34] and to conduct a biochemical screening
when the patient has new evidence of a tumor in the MRI or
Table 2 Predictors for remission
Predictors for remission Studies
• Identification of the tumor pre-surgery by MRI Bochicchio et al. 1995 [7], Chee et al. 2001 [21]
• No invasion of the sinus cavernosus by the adenoma Cannavo et al. 2003 [116]
• Low postoperative cortisol levels (below normal ranges or not
measurable, <2 µg/dL)
Bochicchio et al. 1995 [7], Liu et al. 2019 [25], Fleseriu et al. 2016
[34], Pieters et al.1989 [117], Lindsay et al. 2011 [118], Aranda et al.
2015 [119], Imaki et al. 2001 [120], Ironside et al. 2018 [121],
Mayberg et al. 2018 [122]
• Low cortisol levels 6–12 weeks after surgery (<35 nmol/l) Toms et al. 1993 [123]
• Long-term replacement therapy required (>1 year), long term of
hypocortisolism (>1 year)
Bochicchio et al. 1995 [7], Bansal et al. 2017 [106]
• Low postoperative ACTH levels (mean 7.9 ng/L or mean 13 pg/ml,
respectively), ACTH value <3.3 pmol/L postoperative
Liu et al. 2019 [25], Kuo et al. 2017 [26], Abellan-Galiana et al.
2019 [124]
• Histological confirmation of adenoma Pouratian et al. 2007 [29], Serban et al. 2020 [125]
• Lower DHEA levels pre-surgery Kuo et al. 2017 [26]
• Lower ACTH levels pre-surgery (mean= 71 ng/L) Liu et al. 2019 [25], Kuo et al. 2017 [26], Selek et al. 2018 [126]
• Significant decrease of BMI post-surgery Kuo et al. 2017 [26]
• Experience of the surgeon/the center Barker et al. 2003 [20], Honegger et al. 2018 [55], Rees et al. 2002
[127], Serban et al. 2020 [125]
• Age (mean age 35 years; recurrence more often in younger age
below 35 years)
Liu et al. 2019 [25]
• No USP8 mutant coricotroph tumor Albani et al. 2018 [27]
• Short time to recovery from postoperative adrenal insufficiency Berr et al. 2015 [28]
• Postoperative cortisol response to desmopressin (delta < 193 nmol/l),
low cortisol and ACTH peak after desmopressin, response to
desmopressin after 6 months
Romanholi et al. 2008 [128], Valero et al. 2004 [129], Vassiliadi
et al.2016 [130], Losa et al. 2009 [131], L Marc’hadour et al. 2015
[132], Barbot et al. 2013 [133], Losa et al. 2001 [134], Cambos et al.
2020 [42]
• Post-surgery 11-deoxycortisol < 150 nmol/l after metyrapone-test van Aken et al. 1997 [135]
• Cortisol < 49 nmol/L in a 48 h suppression test with betamethasone
2 mg/day
Uvelius et al. 2018 [136]
Endocrine
worsening/onset of symptoms and comorbidities that might
be related to CS [34]. In an expert statement, Geer et al.
suggested a complex and detailed scheme, taking into
account the time passed since pituitary surgery, the
requirement for steroid replacement therapy, and previous
clinical and biochemical evidence of remission [35]. Sug-
gested test intervals vary between 2 and 6 months. The
overarching premises of these quite different recommenda-
tions is patient safety and cost effectiveness, within the
frame of different health care systems. An additional factor
to be considered is that close surveillance of patients can
have a negative impact on well-being, similar to cancer
patients who are reminded every time at posttreatment sta-
ging on their cancer history. As the vast majority all of
recurrences occur in the first 10 years after pituitary surgery
as shown in the meta-analysis by Roelfsema [2], we
recommend as an minimum compromise an annual screen-
ing of patients with CD in the first 10 years after surgery. A
study by Psaras et al. with 33 patients with CD revealed that
84.5% are followed-up by endocrinologists and only 9.1%
of patients are not under aftercare at all, which is all in all
satisfying but leaves room for improvement [36].
Are there data on clinical evidence of recurrence in
CD?
While there are different studies focusing on the biochem-
ical recurrence of CD, the clinical course has seldom been
addressed by studies—and never as a sole parameter but
always in combination with biochemical results [4].
Therefore, questions remain, i.e., whether there is a certain
sequence of events in which signs and symptoms recur.
Studies addressing these aspects might be of value regard-
ing treatment and screening decisions. The lack of studies
addressing this topic is surprising when considering that
there is still a debate on how to define recurrence bio-
chemically [37].
Biochemical evidence for recurrence
Diagnosis of recurrence is comparable to the diagnostic
process at first diagnosis. Biochemical screening consists of
the LDDST, the late-night salivary cortisol and the cortisol
in a 24 h collection (UFC). In addition, a distinct increase of
plasma ACTH can be helpful to further support the presence
of recurrence. Of these tests, midnight salivary cortisol is
the first test to become abnormal [38, 39], followed by
LDDST, while UFC appears to be least sensitive [12], most
likely because of the use of immunoassays with inappro-
priately wide normal ranges and unspecified cross-reactivity
of the primary antibody with other steroids. However, in a
study with 38 patients by Castinetti, a combined dex-
amethasone desmopressin test was an early marker for
recurrence before other tests showed abnormal results [40].
The test was conducted 6 and 12 months after surgery and
after that yearly. Similarly, Ambrogio et al. showed that the
desmopressin test might be helpful to detect recurrence
early [41]. In this study, desmopressin test was performed
immediately after surgery (<1 week) and in the follow-ups
(after a few months and yearly). A recent study reported that
a cortisol response during the desmopressin test, performed
in the first 3 month of the postoperative phase of hypo-
cortisolism, might be quite predictive [42].
In a study by Atkinson et al., a significant number of
patients had recurrence with cyclic hypercortisolism, sug-
gesting that repetitive measurements of urine and salivary
samples are crucial [6]. Further diagnostic subtyping, such
as CRH stimulation test, the high-dose dexamethasone
suppression test, or inferior sinus petrosal sampling is per se
not required because the origin of hypercortisolism, based
on positive histopathology and/or postoperative tertiary
adrenal insufficiency, is obvious. Exceptions may be the
rare case of cyclic CS of unknown origin in which the
switch to ‘off’ phase’ coincided with the time of pituitary
surgery, causing a diagnostic riddle.
Imaging to detect recurrence
Failure to identify the tumor pre-surgery by MRI is asso-
ciated with a higher rate of persistence and recurrence in
several studies [7, 21]. A similar scenario should apply to
patients with negative MRI at recurrence although no study
has reported MRI positivity rates in the recurrence situation.
It can be assumed that the adenoma should be located on the
same side as initially [43]; in a study by Hofmann et al., the
recurrent adenoma was always located on the same side as
initially [44]. An inferior petrosal sampling can be helpful
[15] to identify the location of the coricotroph adenoma
(right or left)—at least in 70% of cases [45] in the setting of
first surgery. However, there is no consensus whether to use
inferior petrosal sampling solely for this purpose, and post-
operative changes in venous anatomy may further reduce
its value.
In a review by Vitale et al. the authors recommended to
use three Tesla MRI in patients with negative standard 1.5
Tesla MRI and to use an optimized MRI protocol [46]. In a
recent study with 23 patients with CD and a negative stan-
dard MRI, the combination of post-contrast FLAIR sequen-
ces and post-contrast 3D-GRE sequences was helpful in
otherwise pre-operative undetectable microadenomas [47], as
all five adenomas invisible by standard MRI were detectable
by post-contrast FLAIR sequences. Grober et al. conducted a
study with different MRI techniques to detect microadenoma,
showing that a spoiled-gradient echo 3D T1 sequence has a
higher sensitivity than dynamic contrast-enhanced MRIs and
conventional MRI in surgery-naïve patients [48].
Endocrine
New imaging technologies such as the combination of
MRI and PET were recently studied in 35 patients with
therapy- naïve CD. While diagnostic accuracy using MRI
was only 40%, the adenoma could be detected with the
combination of methionine-PET/3.0 Tesla MRI in 100% of
cases and with FDG-PET/3.0 Tesla MRI in 73% of cases
[49]. The value of methionine PET-imaging to detect ade-
nomas was also shown in another study with smaller sample
size [50]. As shown in a different study, simultaneously
CRH stimulation may improve the detection rate of ade-
nomas by FDG-PET [51]. Unfortunately, there are no stu-
dies exclusively focusing on patients with recurrent disease.
Treatment options after recurrence and in
persistent Cushing’s syndrome
Persistency versus recurrence
Treatment options in both scenarios are comparable with
only little differences (overview: Fig. 1, Table 3). In per-
sistent disease, it might be necessary to repeat or add
diagnostic tests such as the inferior sinus petrosus sampling
or to conduct further imaging to exclude an ectopic CS
definitely. Furthermore, while a second pituitary surgery is
normally the first treatment option in recurrent CD, it might
not be in persistent CD with invasive growth of the ade-
noma. In these cases, when a complete removal of the tumor
by surgery is unlikely, radiation therapy might be a more
preferable option.
Second pituitary surgery (TSS)
The value of a second pituitary surgery was already shown
in 1989 by Friedman et al. [52]. It has to be differentiated
between a second TSS performed shortly after first TSS in
persistent disease and a second TSS in recurrent disease. In
persistent disease, the surgery is usually performed early
(days to 4 weeks) before scar tissue has been developing
[53]. Remission rate in persistent disease is about 54%
while remission rates are higher (64%) in recurrent disease.
A thorough review of outcomes in persistent versus recur-
rent CD can be found in Rubinstein et al. [54]. Pituitary
surgery should be conducted in a center with high experi-
ence (more than 25 surgeries per year [55])—this applies
both for persistent, recurrent, and surgery-naïve CD as well.
A second pituitary surgery seems to be currently the first-
line therapy in recurrent CD with a mean remission rate of
64%, but high rates of variability (38–90%) is reported in
the literature [54]. Success rates seem to be lower than in
first surgery [56]. Second TSS has more complication due
to scar tissue in the pituitary. The risk of hypopituitarism is
higher due to a more aggressive surgery [57], with inci-






Second TSS: variable sucess rates between 38-90%, 
hypopituriasm
radiation therapy: sucess rates between 40-70%, delayed mode of 
action, hypopituriasm 
medical therapy: variable control rates between 25 and 60%
bilateral adrenalectomy: 100% sucess rate, lifelong GC-replacement, 
risk of adrenal crises, lifelong mineralocorcicoid-replacement
Fig. 1 Treatment options after recurrence [93]
Table 3 Advantages and disadvantages of different treatment options
Therapy Advantages Disadvantages Success rates
Second or third pituitary
surgery




• Very variable success rates
• Risk of surgery
Mean 64% (38–90%)
Radiation therapy • Can be performed in patients that




• Delayed mode of action; combination
with medical therapy mandatory
• Several treatment sessions in
unfractionated radiation therapy
40–70% [137]
Medical therapy • Can be performed in patients that






• High costs over the long term
25–60% (dependent on drug)
[137], up to 82% for mitotane [75]
Bilateral adrenalectomy • Definitive therapy
• 100% success rate
• Life-long adrenal insufficiency,
patients are at risk of addison’s crisis
• Risk of Nelson Tumor




Radiation therapy can be conducted as conventional radio-
therapy (fractionized over 25–30 sessions) or as stereotactic
(unfractionated, single-dose) radiosurgery. In case of a
negative MRI scan, radiosurgery should be delivered to the
area of the adenoma at time of first diagnosis, while
radiotherapy is delivered in this scenario to the region of the
whole pituitary.
Radiotherapy is a valid therapeutic option, with median
remission rates of 80% (123 patients in 7 studies), no
recurrence rate and a median time to remission of 8 months
[60]. However, cabergoline must not be used during
radiotherapy, as it may increases recurrence rate due to a
recently published study [61]. New hypopituitarism is a
common problem in up to 38 [62]–40% of patients [63].
Other severe side effects are rare (optic neuropathy, radia-
tion induced second tumors) [64] and the 10 year survival
rate was very high with 95% in one study [64]. Response to
radiotherapy does not correlate with sex, age, or severity of
disease [65].
Stereotactic radiosurgery was introduced in Sweden in
1969 by Lars Leksell but was not widespread used to treat
ACTH-producing adenomas in other countries until the
1980s [66]. Success of this treatment options depends on the
size and location of the tumor. Obviously, best results are
achieved in well-defined tumors [67]. Published remission
rates are slightly lower than for fractionized radiotherapy: In
a retrospective study with 68 patients, gamma knife radio-
surgery turned out to be quite effective, leading to remission
in 76% of patients within the next 5 years. Escape rate
following radiosurgery was 13%, and 23% of patients suf-
fered from new pituitary deficiencies [68]. Another study
with 43 patients reported a remission rate of 63% [69]. A
higher escape rate of 18% was reported in an international,
multicenter study with 278 patients [70]. Forty-two percent
of patients developed new hypopituitarism when stereotactic
proton radiosurgery was used [71]. Remission rate using
Cyberknife were lower in one study, reporting a remission
rate of 57%, but the study population was very small (seven
patients) and patients had CD with sinus cavernosus inva-
sion [72]. Severe side effects with transient visual loss and
permanent diplopia were seen in 2 out of 20 patients in
another study [73]. Importantly, experience of the center is
associated with remission rate [74].
The main disadvantage of radiation therapy is the rela-
tively long time to remission. A combination with medical
therapy is always required to bridge the time between
radiation and remission. Effective medical control should be
proven before initiation of radiation therapy. Continuous
endocrine surveillance is mandatory to detect hypopitui-
tarism early and also to adjust medical treatment.
Medical therapy
Medical therapy can be used short-term but is also sui-
table for long-term control. Side effects are specific for
each drug (Table 4). Medical therapy is pituitary-directed
(pasireotide and cabergoline), adrenal-directed (ster-
oidogenesis inhibitors metyrapone, ketoconazole, mito-
tane and etomidate) and glucocorticoid-receptor directed
(mifepristone), the last one currently not being approved
in Europe. Efficacy of all drugs is quite variable; it is very
high for steroidogenesis inhibitors and mifepristone, but
lower for pasireotide and cabergoline [75]. Medical
therapy can either be conducted as monotherapy or in
combination with radiation therapy. Many drugs may be
combined with each other; treatment can be performed as
a block-and-replace-strategy or by titration of the drugs.
Pituitary-directed medical therapy is reserved for CD
while all the other drugs can be given in all forms of CS.
Pasireotide is more effective in patients with mild or
moderate hypercortisolism, with urinary free cortisol
levels of up to two-times the normal range reaching
control rates in ~40% [76]. Pasireotide treatment also
leads to reduction of tumor volume [77]. Cabergoline is
effective in up to 40% of patients, but 22% of patients
escaped from remission over the long-term [78]. Adrenal
steroidogenesis inhibitors block one or more enzymes in
the steroidogenesis pathway. Glucocorticoid receptor
blockers reduce the activity of cortisol on the gluco-
corticoid receptor. Advantages of medical therapy include
the lower risk for adrenal insufficiency than by surgery
and no risk for hypopituitarism. They are relatively safe
to us if administered correctly. As their effect is
immediate, they are the first choice in emergency situa-
tions with severe hypercortisolism. Medical therapy is
also an option for patients who are no suitable candidates
for surgery due to comorbidities. Disadvantages include
the side effects of the medication, the high costs when
used over a long-time period and the fact, that it is not a
definite therapy. Furthermore, escape phenomena are
possible (though seldom) leading to a recurrence of
hypercortisolism.
New adrenal steroidogenesis blockers and glucocorticoid
receptor blockers such as osilodrostat [79], levoketocona-
zole [80], or relacorilant [81] are currently tested in phase II
and phase III studies. There are also trials on new pituitary-
directed drugs (for example retinoic acid) [82].
Although medical therapy can lower cortisol levels,
according to a recent meta-analysis data regarding the
clinical improvement or quality of life in patients treated
with medical therapy are rare [75]. Also, it is unclear if
medical therapy has different effects in patients with ther-
apy-naïve CD or in patients with recurrent CD.
Endocrine
Bilateral adrenalectomy
Bilateral adrenalectomy is considered as an emergency
option in severe and uncontrolled hypercortisolism [83] or
as a last option, when other treatment options are unsuc-
cessful or not well-tolerated. Bilateral adrenalectomy is a
definitive therapy with a success rate of 100%. In a recent
metanalysis, it has been shown that besides being a safe
treatment option with a surgical mortality of 3% [84], it also
improves comorbidities and leads to an improvement of
health-related quality of life [85]. The reasons why bilateral
adrenalectomy is considered ultima ratio, are Nelson’s
syndrome and permanent adrenal insufficiency. Nelson’s
syndrome develops with a prevalence between 8 and 29%
in studies with patient populations over 40 years [86].
Nelson’s syndrome, defined as cortisotroph tumor pro-
gression, is diagnosed by elevated plasma ACTH levels,
hyperpigmentation, and tumor growth [87]. One study
suggests that Nelson’s syndrome can be prevented by a
prophylactic radiation therapy [88] but evidence for this
approach is low, so it is not officially recommended. A
hypophysectomy is seldom required [88]. The need for life-
long hydrocortisone and fludrocortisone replacement ther-
apy with the risk of having adrenal crises is the other main
disadvantage of bilateral adrenalectomy.
Treatment recommendations in biochemical
and clinical mild recurrence
In patients with very mild hypercortisolism and no clinical
signs of active CS, a wait and watch strategy can be prac-
ticed if there remain doubts on a recurrence. However, as
known from patients with subclinical adrenal CS, cardio-
vascular outcome can be negatively influenced even by mild
hypercortisolism [89]. Based on our clinical experience, we
highly recommend to start treatment early in recurrent dis-
ease to improve both quality of life and long-term outcome.
Carroll et al. showed in a study with 15 patients that
patients benefit from early initiation of second-line treat-
ments in terms of weight-loss, improvement of hypertension
and Hba1c, and improved quality of life, respectively. Of
the 15 patients, 12 had normal UFC at time of recurrence,
whereas the 1 mg dexamethasone suppression test was
abnormal in 11 of 15, and 14 had abnormal late night
salivary cortisol levels [90].
Keeping this in mind, we recommend to start treatment
in these patients early, for example with low dose metyr-
apone, ketoconazole, or pasireotide in patients with negative
MRI. Treatment with pasireotide might be a treatment
option in patients with mild hypercortisolism [76] since
success rate depends on the degree of hypercortisolism. In
















































































































































































































































































































































































































































should be considered early on. Comorbidities such as dia-
betes, arterial hypertension, and osteoporosis should always
be treated adequately in parallel. Also, depression elevates
the risk of cardiovascular diseases [91] and should be
treated.
Special remarks on recurrence of CD during
pandemics
Due to an expert consensus, diagnosis and treatment of
recurrent CD must not be delayed due to pandemic crisis
such as the currently worldwide COVID-19-Crisis. On the
other hand—as patients with CD are immunocompromised
and at risk of infections—alternative consultation ways such
as video and telephone might be used. Strict adherence to
social distancing recommendations are highly recommended.
Furthermore, medical treatment might be the first-line ther-
apy in this scenario as treatment should not be delayed by
extensive diagnostic procedures, however, hypercortisolism
should be controlled as soon as possible [92].
Overall recommendations: expertize and
interdisciplinary tumor boards
Patients benefit from treatment by an experienced endocri-
nologist and neurosurgeon; the same applies for the diag-
nostic process and treatment decisions. As CD is a rare and
complex disease, we highly recommend that patients should
be treated in an experienced center that is specialized in CS.
For treatment decisions, interdisciplinary tumor board have
proven their worth.
Summary and conclusion
Recurrence is a common problem in patients with CD
occurring in around 15% of patients. The time to relapse
varies between 3 and 158 months (mean 51 months), and
50% of relapses occur during the first 50 months after initial
surgery. Annual clinical screening is recommended. In case
of clinical and biochemical evidence of recurrence, co-
morbidities should be immediately treated and the best option
for secondary treatment should be selected. This decision
requires a high level of expertize and transfer of the patient to
a tertiary center is highly advised. If second TSS, radiation
therapy or long-term medical therapy are no options, bilateral
adrenalectomy is indicated with immediate control of
hypercortisolism and improved long-term outcome.
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